Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.38 |
| ▸ | ATR | Q13535 | 5/20 | 0.37 |
| ▸ | ATRIP | Q8WXE1 | 4/20 | 0.37 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
| ▸ | MAT2A | P31153 | 1/20 | 0.32 |
| ▸ | MAT1A | Q00266 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27000760 | 0.89 | PRKAB2 (0.39) | ROCK2ATRATRIPPIK3R2P2RX7 | |
| SCHEMBL27000364 | 0.86 | ATR (0.35) | ROCK2ATRATRIPPIK3R2PTPN11 | |
| SCHEMBL27000337 | 0.85 | ATR (0.38) | ROCK2ATRATRIPPIK3R2 | |
| SCHEMBL27000878 | 0.84 | GBA1 (0.39) | ROCK2ATRATRIPPIK3R2MAP3K12 | |
| SCHEMBL27000994 | 0.82 | ATR (0.48) | ATRATRIPPIK3R2 | |
| SCHEMBL26998319 | 0.81 | P2RX7 (0.36) | ROCK2ATRATRIPP2RX7 | |
| SCHEMBL26998317 | 0.81 | ROCK2 (0.36) | ROCK2ATRATRIP | |
| SCHEMBL27000900 | 0.81 | ATR (0.43) | ROCK2ATRATRIPPIK3R2P2RX7 | |
| SCHEMBL26998315 | 0.81 | PIK3CD (0.44) | ROCK2ATRATRIPPIK3R2 | |
| SCHEMBL27000783 | 0.79 | ATR (0.48) | ROCK2ATRATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | ROCK2 1771/4885ATR 277/4885ATRIP 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.